10 reports of this reaction
4.5% of all DEXTROMETHORPHAN HBR AND GUAIFENESIN reports
#1 most reported adverse reaction
COVID 19 is the #1 most commonly reported adverse reaction for DEXTROMETHORPHAN HBR AND GUAIFENESIN, manufactured by Cardinal Health 110, LLC. DBA Leader. There are 10 FDA adverse event reports linking DEXTROMETHORPHAN HBR AND GUAIFENESIN to COVID 19. This represents approximately 4.5% of all 224 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HBR AND GUAIFENESIN who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 is moderately reported among DEXTROMETHORPHAN HBR AND GUAIFENESIN users, representing a notable but not dominant share of adverse events.
In addition to covid 19, the following adverse reactions have been reported for DEXTROMETHORPHAN HBR AND GUAIFENESIN:
The following drugs have also been linked to covid 19 in FDA adverse event reports:
COVID 19 has been reported as an adverse event in 10 FDA reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 accounts for approximately 4.5% of all adverse event reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN, making it one of the most commonly reported side effect.
If you experience covid 19 while taking DEXTROMETHORPHAN HBR AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.